Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1986 1
1987 1
1988 5
1989 1
1991 1
1992 3
1994 1
1995 5
1996 4
1997 10
1998 4
1999 4
2000 4
2001 1
2002 1
2003 1
2004 1
2005 4
2006 3
2007 6
2008 9
2009 12
2010 12
2011 15
2012 10
2013 8
2014 10
2015 14
2016 18
2017 4
2018 2
2019 2
2020 5
2021 7
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Gene therapy.
Kay MA, Liu D, Hoogerbrugge PM. Kay MA, et al. Among authors: hoogerbrugge pm. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12744-6. doi: 10.1073/pnas.94.24.12744. Proc Natl Acad Sci U S A. 1997. PMID: 9398067 Free PMC article. Review.
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Bielack SS, et al. Among authors: hoogerbrugge pm. J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. J Clin Oncol. 2015. PMID: 26033801 Free PMC article. Clinical Trial.
Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.
Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, van der Velden V, Beverloo HB, Bierings M, Dors N, de Haas V, Hoogerbrugge P, Van der Sluis I, Tissing W, Veening M, Boer J, Den Boer M. Pieters R, et al. Among authors: hoogerbrugge p. J Clin Oncol. 2023 Sep 1;41(25):4130-4142. doi: 10.1200/JCO.22.02705. Epub 2023 Jul 17. J Clin Oncol. 2023. PMID: 37459571
Immunocombination therapy for high-risk neuroblastoma.
Kroesen M, Lindau D, Hoogerbrugge P, Adema GJ. Kroesen M, et al. Among authors: hoogerbrugge p. Immunotherapy. 2012 Feb;4(2):163-74. doi: 10.2217/imt.11.169. Immunotherapy. 2012. PMID: 22394368 Review.
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM. Ceolin V, et al. Among authors: hoogerbrugge p. Leukemia. 2023 Jan;37(1):53-60. doi: 10.1038/s41375-022-01740-9. Epub 2022 Oct 30. Leukemia. 2023. PMID: 36310183
Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.
Eckert C, Parker C, Moorman AV, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S, Révész T, Hoogerbrugge P, Hancock J, Sutton R, Henze G, Chen-Santel C, Attarbaschi A, Bourquin JP, Sramkova L, Zimmermann M, Krishnan S, von Stackelberg A, Saha V. Eckert C, et al. Among authors: hoogerbrugge p. Eur J Cancer. 2021 Jul;151:175-189. doi: 10.1016/j.ejca.2021.03.034. Epub 2021 May 16. Eur J Cancer. 2021. PMID: 34010787 Free article.
HDAC inhibitors and immunotherapy; a double edged sword?
Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. Kroesen M, et al. Among authors: hoogerbrugge pm. Oncotarget. 2014 Aug 30;5(16):6558-72. doi: 10.18632/oncotarget.2289. Oncotarget. 2014. PMID: 25115382 Free PMC article. Review.
The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia.
Østergaard A, Enshaei A, Pieters R, Vora A, Horstmann MA, Escherich G, Johansson B, Heyman M, Schmiegelow K, Hoogerbrugge PM, den Boer ML, Kuiper RP, Moorman AV, Boer JM, van Leeuwen FN. Østergaard A, et al. Among authors: hoogerbrugge pm. Hemasphere. 2023 May 4;7(5):e875. doi: 10.1097/HS9.0000000000000875. eCollection 2023 May. Hemasphere. 2023. PMID: 37153875 Free PMC article.
Targets for active immunotherapy against pediatric solid tumors.
Jacobs JF, Coulie PG, Figdor CG, Adema GJ, de Vries IJ, Hoogerbrugge PM. Jacobs JF, et al. Among authors: hoogerbrugge pm. Cancer Immunol Immunother. 2009 Jun;58(6):831-41. doi: 10.1007/s00262-008-0619-x. Epub 2008 Nov 14. Cancer Immunol Immunother. 2009. PMID: 19009292 Free PMC article. Review.
164 results